Martin Drysdale

Martin has over 30 years’ experience in drug discovery across large pharma and biotech as well as charity funded and not-for-profit institutes in both the UK and US. After an Industrial post-doc with Parke-Davis at the PD site in Cambridge, UK, Martin spent time at Wellcome and GlaxoWellcome before leaving to become Head of Chemistry at RiboTargets (Cambridge, UK). Through a series of mergers and acquisitions RiboTargets became Vernalis, where Martin was ultimately Director of Chemistry & Structural Biology (as well as Deputy Research Director). More recently, Martin established the Drug Discovery Unit within the Cancer Research UK (CRUK) Beatson Institute in Glasgow, Scotland, and was Director of the Center for the Development of Therapeutics (CDoT) at the Broad Institute of MIT and Harvard.